Magnetic targeting of drug-conjugated iron oxide nanoparticles has the potential to increase the concentration of therapeutic agents to tumours whilst reducing off-target side effects of current chemotherapy methods. This preclinical work demonstrates that SPION accumulation can be increased in subcutaneous tumours using magnetic fields and can then be detected by MRI. In addition, key physiological parameters can be measured before magnetic targeting for future optimisation of the strategy.
This abstract and the presentation materials are available to members only; a login is required.